Literature DB >> 30505585

Multiple primary malignancies in patients with anal squamous cell carcinoma.

Diana Li1, Nikhil Yegya-Raman1, Sinae Kim2,3, Shridar Ganesan4, Mutlay Sayan1, David August5, Kristen Spencer4, Lara Hathout1, Nell Maloney-Patel5, Usha Malhotra4, Ning J Yue1, Salma K Jabbour1.   

Abstract

Prior studies examining the risk of second primary malignancy (SPM) after a first primary cancer generally have used large datasets such as the Surveillance, Epidemiology, and End Results (SEER) registry and excluded survivors of previous primaries and developers of synchronous primaries. The goal of this study was to provide a more complete representation of multiple cancer risk in squamous cell carcinoma of the anus (SCCA) patients. A single-institution retrospective study of 46 patients treated definitively for SCCA between January 2006 and July 2017 was conducted. Of the 46 patients, 18 (39%) had either a primary malignancy before SCCA (n=9) or SPM after an index SCCA (n=9). Six patients had ≥3 total malignancies. In our cohort, patients without SPMs tended to die from SCCA recurrence, while patients with SPMs were more likely to die from their SPM than from SCCA. Our study suggests that patients with SCCA are often either survivors of previous cancers or develop later malignancies. Several risk factors may play a role including HPV infection, HPV-related or treatment-related immunosuppression, somatic mutations due to chemotherapy, and genetic factors. Patients with SCCA require lifelong surveillance given their elevated risk of malignancy. Future work should focus on identifying genomic or immunologic factors that may predispose SCCA patients to develop multiple primary malignancies.

Entities:  

Keywords:  Anal cancer; chemoradiotherapy; second primary malignancy (SPM)

Year:  2018        PMID: 30505585      PMCID: PMC6219985          DOI: 10.21037/jgo.2018.06.07

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  14 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Authors:  Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman
Journal:  J Natl Cancer Inst       Date:  2015-04-29       Impact factor: 13.506

3.  Second Primary Malignancy in Anal Carcinoma--A US Population-based Study.

Authors:  Binay Kumar Shah; Nibash Budhathoki
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

4.  Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.

Authors:  Amy Berrington de Gonzalez; Rochelle E Curtis; Stephen F Kry; Ethel Gilbert; Stephanie Lamart; Christine D Berg; Marilyn Stovall; Elaine Ron
Journal:  Lancet Oncol       Date:  2011-04       Impact factor: 41.316

5.  Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer.

Authors:  Rebecca A Nelson; Lily L Lai
Journal:  Cancer       Date:  2017-06-13       Impact factor: 6.860

6.  Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.

Authors:  Saly Al-Taei; Russell Banner; Ned Powell; Mererid Evans; Nachi Palaniappan; Zsuzsanna Tabi; Stephen Man
Journal:  Cancer Immunol Immunother       Date:  2013-10-22       Impact factor: 6.968

7.  Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study.

Authors:  Florent Neumann; Jérémie Jégu; Christiane Mougin; Jean-Luc Prétet; Anne-Valérie Guizard; Bénédicte Lapôtre-Ledoux; Simona Bara; Véronique Bouvier; Marc Colonna; Xavier Troussard; Brigitte Trétarre; Pascale Grosclaude; Michel Velten; Anne-Sophie Woronoff
Journal:  Prev Med       Date:  2016-06-28       Impact factor: 4.018

8.  Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

Authors:  Nicholas Donin; Christopher Filson; Alexandra Drakaki; Hung-Jui Tan; Alex Castillo; Lorna Kwan; Mark Litwin; Karim Chamie
Journal:  Cancer       Date:  2016-07-05       Impact factor: 6.860

9.  Five-year relative survival for human papillomavirus-associated cancer sites.

Authors:  Hilda Razzaghi; Mona Saraiya; Trevor D Thompson; S Jane Henley; Laura Viens; Reda Wilson
Journal:  Cancer       Date:  2017-11-06       Impact factor: 6.860

Review 10.  Human viruses and cancer.

Authors:  Abigail Morales-Sánchez; Ezequiel M Fuentes-Pananá
Journal:  Viruses       Date:  2014-10-23       Impact factor: 5.048

View more
  1 in total

1.  Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.

Authors:  Krupa S Jani; Shou-En Lu; James D Murphy; Paul B Romesser; Krishan R Jethwa; Diana Li; Anupama Chundury; Abraham J Wu; Lara Hathout; Christopher L Hallemeier; Salma K Jabbour
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.